Palvella Therapeutics Reports Positive Phase 2 Study Results

The latest update is out from Palvella Therapeutics ( (PVLA) ).

On December 15, 2025, Palvella Therapeutics announced positive topline results from their Phase 2 TOIVA study of QTORIN™ 3.9% rapamycin anhydrous gel for treating cutaneous venous malformations. The study achieved statistical significance on multiple efficacy endpoints, with 73% of participants showing improvement. These results could impact the company’s operations by advancing discussions with the FDA for Breakthrough Therapy Designation and a Phase 3 pivotal study, potentially positioning Palvella as a leader in addressing this unmet medical need.

The most recent analyst rating on (PVLA) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.

Spark’s Take on PVLA Stock

According to Spark, TipRanks’ AI Analyst, PVLA is a Neutral.

Palvella Therapeutics’ overall score reflects significant financial challenges, particularly in revenue and profitability, which are partially offset by a robust cash position and no debt. Positive corporate developments, such as clinical advancements and strategic financing, provide potential growth opportunities. However, valuation concerns due to negative earnings and the absence of dividends weigh on the score.

To see Spark’s full report on PVLA stock, click here.

More about Palvella Therapeutics

Palvella Therapeutics, Inc. is a company operating in the biotechnology industry, focusing on developing first-in-disease therapies for patients with rare skin diseases. Their primary product in development is QTORIN™ 3.9% rapamycin anhydrous gel, aimed at treating cutaneous venous malformations, a significant unmet medical need in the vascular malformations field.

Average Trading Volume: 213,718

Technical Sentiment Signal: Buy

Current Market Cap: $1.17B

See more insights into PVLA stock on TipRanks’ Stock Analysis page.